Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy
AuthorsGreenough, Thomas C.
Cunningham, Coleen K.
McManus, Margaret M.
Sullivan, John L.
UMass Chan AffiliationsDepartment of Molecular Genetics and Microbiology
Department of Medicine, Division of Diabetes
Program in Molecular Medicine
Department of Pediatrics
*Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Gene Products, gag
Immunology and Infectious Disease
MetadataShow full item record
AbstractA trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.
SourceVaccine. 2008 Dec 9;26(52):6883-93. Epub 2008 Oct 20. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/43476
Related ResourcesLink to Article in PubMed